Literature DB >> 33150437

Epidemiological characteristics of patients with severe COVID-19 infection in Wuhan, China: evidence from a retrospective observational study.

Fang Wang1, Jinhong Cao1, Yong Yu2, Jianbo Ding3, Ehab S Eshak4,5, Keyang Liu4,6, Sumaira Mubarik1, Fang Shi1, Haoyu Wen1, Zixin Zeng1, Jianjun Bai1, Chuanhua Yu1,7.   

Abstract

BACKGROUND: The new coronavirus (COVID-19) rapidly resulted in a pandemic. We report the characteristics of patients with severe or critical severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Wuhan city, China, and the risk factors related to infection severity and death.
METHODS: We extracted the demographic and clinical data of 7283 patients with severe COVID-19 infection from designated Wuhan hospitals as of 25 February 2020. Factors associated with COVID-19 critical illness and mortality were analysed using logistic- and Cox-regression analyses.
RESULTS: We studied 6269 patients with severe COVID-19 illness and 1014 critically ill patients. The median (IQR) age was 64 (53-71) years; 51.2% were male, 38.9% were retirees and 7.4% had self-reported histories of chronic disease. Up to the end of the study, 1180 patients (16.2%) recovered and were discharged, 649 (8.9%) died and the remainder were still receiving treatment. The number of daily confirmed critical cases peaked between 23 January and 1 February 2020. Patients with advanced age [odds ratio (OR), 1.03; 95% confidence intervals (CIs), 1.03-1.04], male sex (OR, 1.57; 95% CI, 1.33-1.86) and pre-existing diabetes (OR, 2.11), hypertension (OR, 2.72), cardiovascular disease (OR, 2.15) or respiratory disease (OR, 3.50) were more likely to be critically ill. Compared with those who recovered and were discharged, patients who died were older [hazard ratio (HR), 1.04; 95% CI, 1.03-1.05], more likely to be male (HR, 1.74; 95% CI, 1.44-2.11) and more likely to have hypertension (HR, 5.58), cardiovascular disease (HR, 1.83) or diabetes (HR, 1.67).
CONCLUSION: Advanced age, male sex and a history of chronic disease were associated with COVID-19 critical illness and death. Identifying these risk factors could help in the clinical monitoring of susceptible populations.
© The Author(s) 2020. Published by Oxford University Press on behalf of the International Epidemiological Association.

Entities:  

Keywords:  COVID-19; Wuhan; clinical characteristics; oxygen therapy; pneumonia; risk factors; severity

Mesh:

Year:  2021        PMID: 33150437      PMCID: PMC7665537          DOI: 10.1093/ije/dyaa180

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


In 7283 patients with severe or critical COVID-19 infection, the ratio of severe to critical illness was 6.18. A total of 1180 patients (16.2%) recovered and were discharged, and 649 (8.9%) died. Advanced age, male sex and pre-existing chronic diseases were predictors for critical illness and death. Patients with underlying diseases and living in non-central areas in Wuhan had an increased risk of developing critical COVID-19 illness. The identification of risk factors for disease severity and death could be helpful in early clinical monitoring of disease progression in susceptible populations.

Introduction

In early December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which results in coronavirus disease 2019 (COVID-19),, emerged in Wuhan city, China and spread rapidly throughout China, then around the world, leading to a global pandemic. SARS-CoV-2 is the third coronavirus-induced human epidemic in the past 20 years and one of the major pathogens that primarily targets the human respiratory system. The World Health Organization has characterized the pandemic as an ‘international public-health emergency’ and defined the global risk level as very high., The outbreak, first reported in Wuhan, spread across the country in just a few months, with the number of infections and deaths rising rapidly. However, under the effective control of the government and the assistance of all sectors, the epidemic prevention and control situation across the country has been well developed. According to official reports, the number of newly diagnosed cases in Wuhan started to decrease on 19 February. By 30 April, China had reported a total of 84 385 confirmed cases; of these, 4643 patients died and 78 845 patients recovered. China has gained valuable experience throughout the epidemic; meanwhile, the global situation is intensifying and still very serious. Therefore, it is necessary and important to analyse and share the available Chinese data and experience. In the early stages of the epidemic, a great deal of research focused on epidemic curve modelling and prediction, as well as detection methods and virus characteristics. Recently, some epidemiological studies on COVID-19 have been reported;, however, these studies focused mainly on the clinical and radiological characteristics or were simple studies based on public data. There is a lack of large-sample studies of patients with severe or critical COVID-19 illness with an extremely high risk of death and details of the risk factors associated with severity have not yet been well described. In this study, we retrospectively analysed the clinical data of severely and critically ill COVID-19 patients in designated hospitals in Wuhan, with the aim of identifying risk factors for both the severity of COVID-19 infection and its related mortality, to provide a basis for research and prevention strategies.

Methods

Data sources

The data for this retrospective observational study were collected from the Chinese infectious-disease-reporting information system. According to national Chinese laws and regulations, as a class B infectious disease, all cases of COVID-19 must be immediately reported through the infectious-disease information system, by local hospitals or municipal Centers for Disease Control and Prevention (CDCs) and aggregated to the infectious-disease-reporting system. We systematically screened the case data of patients with COVID-19 from designated third-level medical hospitals in Wuhan (details are in the Supplementary material, eMethods and Supplementary Table 1, available as Supplementary data at IJE online). Our team was among those who participated in obtaining the original uncleared data from the designated hospitals during the epidemic; cleaning, shortening and analysing the original data; sending the data to the CDC and the infectious-disease-reporting information system; and working with CDC staff in ensuring the quality of the data. We were given official approvals for monitoring the data of registered patients with severe and critical COVID-19 illness in Wuhan until 25 February 2020 (i.e. the final date of follow-up in this study). All identifiable personal information was deleted for privacy protection. After excluding duplicate cases, a total of 7283 patients were diagnosed as being severely or critically ill, forming the sample for this study. A flowchart of the study population is presented in Supplementary Figure 1, available as Supplementary data at IJE online. The study design and data analysis were approved by the Ethics Committee of the Medical Department of Wuhan University.

Case definitions

All the patients included in this study were diagnosed with severe or critical COVID-19 illness after laboratory confirmation, according to the diagnostic criteria of the new coronavirus infection pneumonia diagnosis and treatment plan (trial fifth version). The diagnostic criteria were as follows: Severe illness: Patients with dyspnoea or a respiratory rate ≥30 breaths/min (in resting state, refers to oxygen saturation ≤93%) and/or arterial partial pressure of oxygen (PaO2)/oxygen concentration (FiO2) ≤300 mmHg (1 mmHg = 0.133 kPa). Critical illness: Patients who meet any of the following criteria: the occurrence of respiratory failure requiring mechanical ventilation, shock and/or other organ failures that require admission to the intensive care unit.

Variables

We collected hospital-admission data on patient demographics and self-reported history of chronic diseases. Clinical characteristics included the classification of severity (severe or critical illness); date of onset, divided into four periods based on the key time points of China Chunyun (Spring Festival travel season) (December 2019 to 9 January 2020), Wuhan city lockdown (10–22 January 2020), centralized quarantines (23 January to 1 February 2020) and treatment strategies (2–25 February 2020); symptoms from onset to hospital admission (e.g. fever, cough); and clinical oxygen-therapy methods. Time-related indicators included duration from the onset of symptoms to the first day of hospitalization, duration from the onset of symptoms to clinical confirmation and duration from the onset of symptoms to the endpoint (death, recovered and discharged, or end of study on 25 February 2020).

Statistical analysis

The Kolmogorov–Smirnov test was used to test the distribution of the patients’ characteristics. Results of descriptive analyses are presented as medians and interquartile ranges (IQRs) for continuous variables and as counts and percentages in each category for categorical variables. The Kruskal–Wallis test was used to test the differences in normally and non-normally distributed continuous data and the chi-squared test was used to examine the difference in proportions of categorical variables between different groups. The geographical distributions of the newly confirmed COVID-19 cases throughout the four date-of-onset periods are presented using ArcGIS software version 10.6 (Environmental Systems Research Institute Inc). To explore the risk factors associated with severity of COVID-19 (critical illness) and the risk of mortality among severely and critically ill patients until 25 February 2020, univariate and multivariate logistic-regression and Cox proportional-hazards-regression models were used to estimate the odds ratios (ORs) or hazard ratios (HRs) and 95% confidence intervals (CIs). The multivariate model included age (continuous variable), sex (male or female), location (central Wuhan area or suburbs), occupation (retirees, medical workers or others), dichotomous self-reported co-morbidities (yes or no), number of presenting symptoms (continuous variable) and the three later date-of-onset periods in reference to the December 2019 to 9 January 2020 period. The interactions between occupation categories with the presence of any co-morbidities towards the risk of developing critical COVID-19 illness and death were also investigated by adding cross-product terms of these variables to the regression models. All analyses were performed using SPSS, version 22.0 (SPSS Inc).

Results

Characteristics of patients with severe or critical COVID-19 illness

Table 1 shows the general characteristics of the study population. Of the 7283 patients with COVID-19, 86.1% were diagnosed with severe illness and 13.9% with critical illness. The median age was 64 years and 51.2% were men. Among all patients, 76.2% lived in the central area in Wuhan, 38.90% were retirees and 2.2% were medical workers. There were 7.4% of patients who self-reported histories of chronic medical disease: 4.1% had pre-existing hypertension and 2.2% had cardiovascular disease. The prevalence of these chronic diseases was higher among critically ill patients than among severely ill patients. When comparing the presenting symptoms at hospital admission, critically ill patients were more likely to have fever and dyspnoea than severely ill patients.
Table 1.

Baseline characteristics of severe or critically ill COVID-19 patients in Wuhan, China

CharacteristicsaTotal (n = 7283)Classification of severity
P
Severe illness (n = 6269)Critical illness (n = 1014)
Age, yearsMedian (IQR)64 (53–71)63 (52–70)67 (57–75)<0.0001
Age groups, years<40715 (9.8)668 (10.7)47 (4.6)<0.0001
40–592098 (28.8)1863 (29.7)235 (23.2)
60–793803 (52.2)3228 (51.5)575 (56.7)
≥80665 (9.1)509 (8.1)156 (15.4)
SexMale3732 (51.2)3101 (49.5)631 (62.2)<0.0001
Female3551 (48.8)3168 (50.5)383 (37.8)
SourceFrom outpatient and emergency direct admission2828 (38.8)2439 (38.9)389 (38.4)<0.0001
From community/isolation point admission1109 (15.2)1031 (16.4)78 (7.7)
Transferred from another hospital2445 (33.6)2033 (32.4)412 (40.6)
Transferred from an unknown route728 (10)624 (10)104 (10.3)
Missing173 (2.4)142 (2.3)31 (3.1)
LocationCentral area in Wuhan5552 (76.2)4816 (76.8)736 (72.6)<0.0001
Suburban area in Wuhan836 (11.5)685 (10.9)151 (14.9)
Out of city80 (1.1)58 (0.9)22 (2.2)
Missing815 (11.2)710 (11.3)105 (10.4)
OccupationsChildren and students11 (0.2)9 (0.1)2 (0.2)0.0003
Cadres269 (3.7)246 (3.9)23 (2.3)
Individuals and freelancers26 (0.4)25 (0.4)1 (0.1)
Labourers92 (1.3)84 (1.3)8 (0.8)
Public servants299 (4.1)266 (4.2)33 (3.3)
Houseworkers and unemployed1231 (16.9)1046 (16.7)185 (18.2)
Retirees2830 (38.9)2387 (38.1)443 (43.7)
Farmers and migrant workers128 (1.8)103 (1.6)25 (2.5)
Medical workers163 (2.2)146 (2.3)17 (1.7)
Missing2234 (30.7)1957 (31.2)277 (27.3)
Co-morbiditiesDiabetes126 (1.7)69 (1.1)57 (5.6)<0.0001
Hypertension300 (4.1)172 (2.7)128 (12.6)<0.0001
Cardiovascular disease161 (2.2)87 (1.4)74 (7.3)<0.0001
Respiratory disease50 (0.7)23 (0.4)27 (2.7)<0.0001
Any538 (7.4)315 (5)223 (22)<0.0001
Date of onsetDec 2019–9 Jan 2020156 (2.1)118 (1.9)38 (3.7)<0.0001
10–22 Jan 20201417 (19.5)1169 (18.6)248 (24.5)
23 Jan–1 Feb 20203560 (48.9)3111 (49.6)449 (44.3)
2–25 Feb 20202113 (29)1847 (29.5)266 (26.2)
Missing37 (0.5)24 (0.4)13 (1.3)
Symptoms at admissionFever5466 (75.1)4672 (74.5)794 (78.3)0.0099
Diarrhoea663 (9.1)579 (9.2)84 (8.3)0.3283
Fatigue1616 (22.2)1343 (21.4)273 (26.9)0.0001
Cough3721 (51.1)3193 (50.9)528 (52.1)0.5013
Chest stuffiness1323 (18.2)1118 (17.8)205 (20.2)0.0678
Nasal obstruction68 (0.9)59 (0.9)9 (0.9)0.8693
Runny nose79 (1.1)64 (1)15 (1.5)0.1911
Dyspnoea1077 (14.8)852 (13.6)225 (22.2)<0.0001
Number of symptoms at admission0105 (1.4)81 (1.3)24 (2.4)<0.0001
12810 (38.6)2529 (40.3)281 (27.7)
22300 (31.6)1946 (31)354 (34.9)
31331 (18.3)1103 (17.6)228 (22.5)
4493 (6.8)405 (6.5)88 (8.7)
≥5244 (3.4)205 (3.3)39 (3.8)
Initial oxygen therapyUntreated1172 (16.1)1102 (17.6)70 (6.9)<0.0001
Nasal catheter4743 (65.1)4360 (69.5)383 (37.8)
Mask oxygen inhalation293 (4)178 (2.8)115 (11.3)
High-flow oxygen therapy680 (9.3)459 (7.3)221 (21.8)
Non-invasive ventilation188 (2.6)29 (0.5)159 (15.7)
Invasive ventilation58 (0.8)2 (0.03)56 (5.5)
Without record149 (2)139 (2.2)10 (0.99)
Highest oxygen therapyUntreated632 (8.7)616 (9.8)16 (1.6)<0.0001
Nasal catheter3599 (49.4)3455 (55.1)144 (14.2)
Mask oxygen inhalation420 (5.8)340 (5.4)80 (7.9)
High-flow oxygen therapy853 (11.7)677 (10.8)176 (17.4)
Non-invasive ventilation467 (6.4)202 (3.2)265 (26.1)
Invasive ventilation283 (3.9)66 (1.1)217 (21.4)
Without record1029 (14.1)913 (14.6)116 (11.4)
Final oxygen therapyUntreated720 (9.9)698 (11.1)22 (2.2)<0.0001
Nasal catheter1099 (15.1)1046 (16.7)53 (5.2)
Mask oxygen inhalation113 (1.6)85 (1.4)28 (2.8)
High-flow oxygen therapy229 (3.1)132 (2.1)97 (9.6)
Non-invasive ventilation265 (3.6)102 (1.6)163 (16.1)
Invasive ventilation208 (2.9)44 (0.7)164 (16.2)
Without record4649 (63.8)4162 (66.4)487 (48)
Clinical outcomeRecovered1180 (16.2)1150 (18.3)30 (3.0)<0.0001
Continuing treatment5088 (69.9)4581 (73.1)507 (50.0)
Transferredb366 (5)303 (4.8)63 (6.2)
Death649 (8.9)235 (3.7)414 (40.8)
Duration fromSymptom onset to clinical confirmation, median (IQR)11 (7–15.3)11 (7–16)10 (7–15)0.0993
Symptom onset to endpoint, median (IQR)21 (16–27)22 (17–27)19 (14–25)<0.0001
Clinical confirmation to endpoint, median (IQR)10 (6–14)11 (7–15)7 (4–12)<0.0001
Symptom onset to first hospitalization, median (IQR)10 (5–14)10 (6–14)8 (4–13)<0.0001

COVID-19, coronavirus disease 2019; IQR, interquartile range.

Figures are numbers (percentages) unless otherwise specified.

Transferred: by the final follow-up date, patients were transferred to other medical departments or hospitals.

Baseline characteristics of severe or critically ill COVID-19 patients in Wuhan, China COVID-19, coronavirus disease 2019; IQR, interquartile range. Figures are numbers (percentages) unless otherwise specified. Transferred: by the final follow-up date, patients were transferred to other medical departments or hospitals.

Time and geographic characteristics

As shown in Figure 1, the incidence of severe and critical COVID-19 illness peaked between 23 January and 1 February 2020, with nearly 50% of all cases being confirmed in this period. Severe cases accounted for a higher proportion than critically ill cases at this stage; later on, the number of confirmed severe cases decreased. The median duration from onset of symptoms to the endpoint was 22 days in severely ill patients and 19 days in critically ill patients (Table 1).
Figure 1.

Daily and cumulative numbers of severe-diagnosed COVID-19 cases by symptom-onset date.

Daily and cumulative numbers of severe-diagnosed COVID-19 cases by symptom-onset date. The outbreak began in the central area in Wuhan and gradually spread to suburban and rural areas across the four time periods, with the same trend seen for severely and critically ill patients (Figure 2). The geographical difference of confirmed cases was quite large, with the highest incidence in the central districts.
Figure 2.

The geographic distribution of daily rates of COVID-19 cases (A: severe, B: critical illness, C: total) across the four periods in Wuhan, China.

The geographic distribution of daily rates of COVID-19 cases (A: severe, B: critical illness, C: total) across the four periods in Wuhan, China.

Treatment by oxygen therapy

Table 1 shows that 81.9% of patients received initial oxygen therapy, mainly via a nasal catheter (65.1%). The prevalence of initial oxygen therapy by any method was higher in critically ill patients than in severely ill patients, except for nasal-catheter inhalation. During treatment, the most commonly used forms of oxygen therapy for patients were nasal-catheter oxygen therapy and high-flow oxygen therapy.

Clinical outcomes

Until the end of the study on 25 February 2020, of the 7283 severely and critically ill COVID-19 patients, 8.9% of the patients died, 16.2% recovered and were discharged, 5% were transferred to other medical departments or hospitals and the remaining 69.9% were continuing to receive treatment. The distribution of these clinical outcomes varied according to the patients’ characteristics (Supplementary Table 2, available as Supplementary data at IJE online).

Risk factors for the severity of COVID-19 infection

In Table 2, older age, male sex and having pre-existing chronic disease were associated with more severe infection (critical COVID-19 illness); the multivariate ORs (95% CIs) were 1.03 (1.03–1.04) for 1-year increment of age and 1.57 (1.33–1.86) in male patients. The likelihood of developing critical illness increased with an increasing number of presenting symptoms of COVID-19 infection at hospital admission (OR, 1.19 per one-symptom increment). The risk of critical illness tended to decrease across the four time periods; thus, patients with symptomatic onset in the early stage of the epidemic were more likely to develop critical illness. In terms of occupation, retirees showed a higher risk in the univariate model (OR, 1.19; 95% CI, 1.01–1.40); however, after multivariate adjustment for demographic and clinical data, the OR was of an inverse trend (OR, 0.82; 95% CI, 0.68–1.00). Supplementary Table 3, available as Supplementary data at IJE online, shows that there was no interaction between pre-existing chronic disease and retirement towards the risk of developing critical COVID-19 illness.
Table 2.

Logistic-regression analysis of risk factors associated with severity of COVID-19 infection (critical illness) in 7283 patients with COVID-19 in Wuhan

VariablesNumber (%) of critical illness casesUnivariable logistic regressiona
Multivariable logistic regressionb
OR (95% CI) P OR (95% CI) P
Age, years1014 (13.9)1.02 (1.02,1.03)<0.00011.03 (1.03,1.04)<0.0001
Sex
  Female631 (16.9)1 (ref)1 (ref)
  Male383 (10.8)1.68 (1.47,1.93)<0.00011.57 (1.33,1.86)<0.0001
Location
  Central area in Wuhan736 (13.3)1 (ref)1 (ref)
  Other areasc173 (18.9)1.52 (1.27,1.83)<0.00011.62 (1.30,2.04)<0.0001
Occupation
  Medical workers17 (10.4)0.75 (0.45,1.23)0.2711.25 (0.73,2.13)0.423
  Retirees443 (15.7)1.19 (1.01,1.40)0.0340.82 (0.68,1.00)0.045
  Others277 (13.5)1 (ref)1 (ref)
Diabetes
  Yes57 (45.2)5.35 (3.74,7.65)<0.00012.11 (1.32,3.38)0.002
  No957 (13.4)1 (ref)1 (ref)
Hypertension
  Yes128 (42.7)5.12 (4.03,6.51)<0.00012.72 (1.97,3.76)<0.0001
  No886 (12.7)1 (ref)1 (ref)
Cardiovascular disease
  Yes74 (46.0)5.59 (4.07,7.68)<0.00012.15 (1.38,3.33)0.001
  No940 (13.2)1 (ref)1 (ref)
Respiratory disease
  Yes27 (54.0)7.43 (4.24,13.01)<0.00013.50 (1.67,7.34)0.001
  No987 (13.6)1 (ref)1 (ref)
Number of symptoms at admission1014 (13.9)1.19 (1.12,1.26)<0.00011.19 (1.11,1.28)<0.0001
Date of onset*
 Dec 2019–9 Jan 202038 (24.4)1 (ref)1 (ref)
 10–22 Jan 2020248 (17.5)0.66 (0.45,0.97)<0.00010.59 (0.34,1.00)0.051
 23 Jan–1 Feb 2020449 (12.6)0.45 (0.31,0.66)<0.00010.40 (0.24,0.68)0.001
 2–25 Feb 2020266 (13.8)0.45 (0.30,0.66)<0.00010.39 (0.23,0.66)<0.0001

COVID-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval.

P trend = 0.00003 < 0.001.

The model included one variable at a time.

The model included all variables in the table.

Other areas: suburban area in Wuhan and out of city.

Logistic-regression analysis of risk factors associated with severity of COVID-19 infection (critical illness) in 7283 patients with COVID-19 in Wuhan COVID-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval. P trend = 0.00003 < 0.001. The model included one variable at a time. The model included all variables in the table. Other areas: suburban area in Wuhan and out of city.

Risk factors for COVID-19 death

Older age, male sex and pre-existing hypertension, cardiovascular disease and diabetes were associated with increased risk of mortality in COVID-19 patients; the multivariate HRs (95% CIs) were 1.04 (1.03–1.05), 1.74 (1.44–2.11), 5.58 (4.30–7.26), 1.83 (1.33–2.51) and 1.67 (1.22–2.30), respectively (Table 3). As a large proportion of patients were still receiving treatment, with no definite outcome of being discharged alive or death by the end of our study on 25 February 2020, in a sensitivity analysis, we restricted the Cox-regression analysis of COVID-19 death to those with a definite outcome by the study end. Accordingly, we analysed the risk of death in 1829 patients (1180 recovered and discharged and 649 deaths, excluding patients still under treatment or transferred to other facilities with no knowledge of their survival or death status). Similar results were obtained in this sensitivity analysis (Supplementary Table 4, available as Supplementary data at IJE online). There were no associations between occupation and risk of death after adjustment for socio-demographic and clinical factors. There was an interaction between pre-existing chronic disease and retirement towards the risk of death in COVID-19 patients (OR, 0.72; 95% CI, 0.55–0.94).
Table 3.

Cox-regression analysis of risk factors associated with death in 7283 patients with COVID-19 in Wuhan until 25 February 2020

VariablesNumber (%) of deathsUnivariatea
Multivariateb
HR (95% CI) P HR (95% CI) P
Age649 (8.9)1.05 (1.04,1.06)<0.00011.04 (1.03,1.05)<0.0001
Sex
 Female435 (11.7)1 (ref)1 (ref)
 Male214 (6.0)1.98 (1.68,2.33)<0.00011.74 (1.44,2.11)<0.0001
Location
 Central area in Wuhan503 (9.1)1 (ref)1 (ref)
 Other areasc104 (11.3)1.25 (1.01,1.55)0.0401.23 (0.96,1.58)0.108
Occupation
 Medical workers6 (3.7)0.40 (0.18,0.91)0.0280.89 (0.39,2.00)0.760
 Retirees311 (11.0)1.27 (1.05,1.53)0.0110.82 (0.67,0.99)0.041
 Others177 (8.6)1 (ref)1 (ref)
Diabetes
 Yes73 (57.9)9.60 (7.50,12.27)<0.00011.67 (1.22,2.30)0.002
 No576 (8.0)1 (ref)1 (ref)
Hypertension
 Yes174 (58.0)11.86 (9.40,14.14)<0.00015.58 (4.30,7.26)<0.0001
 No475 (6.8)1 (ref)1 (ref)
Cardiovascular disease
 Yes96 (59.6)10.42 (8.36,12.98)<0.00011.83 (1.33,2.51)<0.0001
 No553 (7.8)1 (ref)1 (ref)
Respiratory disease
 Yes32 (64.0)9.40 (6.59,13.42)<0.00011.32 (0.83,2.07)0.238
 No617 (8.5)1 (ref)1 (ref)
Number of symptoms at admission649 (8.9)649 (35.5)<0.00011.07 (0.99,1.16)0.090
Date of onset
 Dec 2019–9 Jan 202024 (15.4)1 (ref)1 (ref)
 10–22 Jan 2020174 (12.3)1.46 (0.89,2.39)0.1341.40 (0.73,2.68)0.314
 23 Jan–1 Feb 2020326 (9.2)1.52 (0.92,2.50)0.0991.73 (0.90,3.33)0.098
 2–25 Feb 2020117 (5.5)1.77 (1.05,2.98)0.0331.93 (0.98,3.81)0.058

COVID-19, coronavirus disease 2019; HR, hazard ratio; CI, confidence interval.

The model included one variable at a time.

The model included all variables in the table.

Other areas: suburban area in Wuhan and out of city.

Cox-regression analysis of risk factors associated with death in 7283 patients with COVID-19 in Wuhan until 25 February 2020 COVID-19, coronavirus disease 2019; HR, hazard ratio; CI, confidence interval. The model included one variable at a time. The model included all variables in the table. Other areas: suburban area in Wuhan and out of city.

Discussion

We report on 7283 severely and critically ill patients with confirmed SARS-CoV-2 infection during the epidemic in Wuhan, China. Critical illness accounted for 13.9% of the cases. Death occurred in 8.9% of patients, of whom 63.8% were critically ill at the time of hospital admission. Older age, male sex and having pre-existing chronic disease were associated with the incidence of critical illness and a higher risk of death. The number of initial symptoms was a risk factor for those presenting with critical illness and those who died. Advanced age has been previously reported as an independent predictor of mortality in SARS, MERS and COVID-19. Some epidemiological observations have shown that all age groups were susceptible to COVID-19 infection and that older men with chronic diseases were more severely affected., Among the confirmed severely and critically ill patients in our study, the prevalence of chronic diseases in men (8.68%) was higher than that in women (6.03%). The proportion of critical illness and the risk of death were higher in men than in women, which is consistent with the findings of previous studies from China suggesting a higher death rate among men compared with women., The exact mechanism for the augmented risk profile in men compared with women is still unclear; however, studies have suggested that the higher level of angiotensin-converting enzyme-2 (ACE2) in men might interact with viruses, rendering them more capable of infecting healthy cells. In addition, men generally have more risky behaviours than women, such as their higher smoking rate, which makes them vulnerable to the risk of mortality. Our univariate analyses showed that the retired population tended to have a higher risk of developing critical illness and a high risk of mortality that vanished after adjusting for socio-demographic and clinical factors. The higher risk of more severe illness and mortality among retirees was more likely attributed to factors such as their advanced age and pre-existing chronic diseases. Controlling for such factors turned the association and interaction to null in retirees. In our study, 44% of the patients who died reported a history of at least one pre-existing chronic disease (hypertension, cardiovascular diseases or diabetes). Those co-morbidities were associated with critical illness and a higher risk of mortality in COVID-19 patientsSARS-CoV-2 is an enveloped RNA virus; it can enter the cell through the ACE2. Studies have shown that the overexpression of ACE2 in highly differentiated airway epithelial cells is the basis of SARS-CoV susceptibility. ACE2 plays an important role in normal physiological activities, to control blood pressure and cardiovascular risk. When hypertensive patients are infected by the novel coronavirus, the blood-pressure-regulation process becomes more complicated and difficult to control, and the risk of cardiovascular, renal and other systemic adverse events in COVID-19 patients will be higher.,, Our study confirmed that not only in general COVID-19 patients, but also in severely and critically ill patients, the role of pre-existing hypertension and cardiovascular disease remains important in regard to death after COVID-19 infection. Patients with diabetes are more likely to have serious complications from the new coronavirus because their high blood-glucose level promotes viral growth, impairs the patient’s immune function and their ability to resist infection, and paves the way for secondary bacterial and viral co-infections. In addition, in the event of diabetes complications, the risk of multiple organ failure and death is greatly increased. One study indicated that mortality and multi-organ damage were significantly higher in COVID-19 patients with type 2 diabetes than in non-diabetic patients (HR, 1.5). Knowledge of these risk factors can guide clinicians to conduct appropriate medical management of patients with COVID-19 and co-morbid cardiovascular disease, and indicate the group of patients in whom the progression of symptoms should be vigorously monitored and controlled. Moreover, our research has also found that the proportion of critically ill patients was higher among those living in suburban areas than among those living in the central areas of Wuhan, and the risk of critical pneumonia infection among residents in suburban areas was also higher than that in central areas. We consider this phenomenon to be related to the distribution of medical resources. More medical resources were concentrated in the central area of Wuhan, whereas accessibility to and the availability of medical services for residents in the suburbs were lower. Over the four periods of the epidemic, the risk of developing critical infection tended to decline. The incidence of severe or critical illness peaked between 23 January and 1 February 2020, followed by a decline. This was largely attributed to the timely initiatives of the Chinese government and the Wuhan authorities. For example, Wuhan had been closed since 23 January. On 11 February, all the residential communities in Wuhan were closed and managed, and the scope was extended to Hubei Province on 16 February. From 24 January, Hubei Province launched a Level 1 emergency response to a public-health emergency. Thanks to the improved diagnostic techniques, increased national attention and hospital treatment capacity over time, patients in the later stages of the epidemic were diagnosed and treated earlier. Under the leadership of the national organization, since 24 January, medical teams have been set up in provinces across the country to go to Wuhan and >35 000 medical staff supported Wuhan, which greatly relieved the pressure of medical care in Wuhan. All these initiatives contributed to the reduced risk of developing critical COVID-19 illness over time. This study has several limitations. The observational-study design precludes causal inference. However, under such public-health emergencies, there is really no way to carry out a more comprehensive study. Moreover, the follow-up time was relatively short and, by the end of the study period, the clinical outcome of more than half of the study’s patients was not yet clear. The data on pre-existing chronic diseases were based on self-report and we could not verify their validity. Also, there was a lack and incompleteness of information on other epidemiological variables, such as body mass index and history of cancer and dyslipidaemia, and clinical characteristics. However, access to such information about a nationwide epidemic is strictly regulated by higher authorities. Currently, we are seeking official approvals to obtain updated and more comprehensive data for further research. In summary, rigorous and timely epidemiological measures are essential to help control the rapid spread of COVID-19 infection. This study sheds light on the risk factors for both the severity of COVID-19 and its related mortality, suggesting that age, sex and pre-existing chronic diseases are independent predictors of more severe disease (critical illness) and a higher risk of death. Patients with underlying diseases living in non-central areas of Wuhan, where limited resources were available, had an increased risk of developing critical COVID-19 illness. The identification of risk factors for COVID-19 severity and mortality in this study could be helpful for early clinical monitoring of disease progression in susceptible populations.

Supplementary data

Supplementary data are available at IJE online.

Author contributions

F.W., J.C., J.B., Z.Z. and C.Y. collected the data. F.W., J.C., Y.Y. and C.Y. performed statistical analyses and F.W. drafted the manuscript. F.W., J.C., J.D., E.S.E., K.L., S.M., F.S., H.W. and C.Y. revised the final manuscript. C.Y. acts as the guarantor for the paper. All authors have read and agree to publish the final manuscript.

Funding

This work was supported by the Fundamental Research Funds for the Central Universities (grant number 2020YJ066), the National Key Research and Development Program of China (grant number 2017YFC1200502, 2018YFC1315302) and the National Natural Science Foundation of China (grant number 81773552, 81273179). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. Click here for additional data file.
  8 in total

Review 1.  The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19.

Authors:  Peter J Richardson; Bruce W S Robinson; Daniel P Smith; Justin Stebbing
Journal:  Vaccines (Basel)       Date:  2022-06-15

2.  Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome.

Authors:  Maria Alice Freitas Queiroz; Pablo Fabiano Moura das Neves; Sandra Souza Lima; Jeferson da Costa Lopes; Maria Karoliny da Silva Torres; Izaura Maria Vieira Cayres Vallinoto; Carlos David Araújo Bichara; Erika Ferreira Dos Santos; Mioni Thieli Figueiredo Magalhães de Brito; Andréa Luciana Soares da Silva; Mauro de Meira Leite; Flávia Póvoa da Costa; Maria de Nazaré do Socorro de Almeida Viana; Fabíola Brasil Barbosa Rodrigues; Kevin Matheus Lima de Sarges; Marcos Henrique Damasceno Cantanhede; Rosilene da Silva; Clea Nazaré Carneiro Bichara; Ana Virgínia Soares van den Berg; Adriana de Oliveira Lameira Veríssimo; Mayara da Silva Carvalho; Daniele Freitas Henriques; Carla Pinheiro Dos Santos; Juliana Abreu Lima Nunes; Iran Barros Costa; Giselle Maria Rachid Viana; Francisca Regina Oliveira Carneiro; Vera Regina da Cunha Menezes Palacios; Juarez Antonio Simões Quaresma; Igor Brasil-Costa; Eduardo José Melo Dos Santos; Luiz Fábio Magno Falcão; Antonio Carlos Rosário Vallinoto
Journal:  Front Cell Infect Microbiol       Date:  2022-06-30       Impact factor: 6.073

Review 3.  Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Abraham Degarege; Zaeema Naveed; Josiane Kabayundo; David Brett-Major
Journal:  Pathogens       Date:  2022-05-10

4.  The Association of Hypertension With the Severity of and Mortality From the COVID-19 in the Early Stage of the Epidemic in Wuhan, China: A Multicenter Retrospective Cohort Study.

Authors:  Sumaira Mubarik; Xiaoxue Liu; Ehab S Eshak; Keyang Liu; Qing Liu; Fang Wang; Fang Shi; Haoyu Wen; Jianjun Bai; Chuanhua Yu; Jinhong Cao
Journal:  Front Med (Lausanne)       Date:  2021-05-12

5.  Incidence and predictors of mortality among COVID-19 patients admitted to treatment centers in North West Ethiopia; A retrospective cohort study, 2021.

Authors:  Belayneh Mengist; Zelalem Animut; Tadesse Tolossa
Journal:  Int J Afr Nurs Sci       Date:  2022-04-30

6.  Molecular diagnosis of SARS-CoV-2 in seminal fluid.

Authors:  D Paoli; F Pallotti; G Nigro; L Mazzuti; M N Hirsch; M B Valli; S Colangelo; C M Mastroianni; G Antonelli; A Lenzi; O Turriziani; F Lombardo
Journal:  J Endocrinol Invest       Date:  2021-04-30       Impact factor: 4.256

7.  Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: a systematic review.

Authors:  Jingwei Li; Yali Wang; Yong Liu; Ziqu Zhang; Yuyun Zhai; Yan Dai; Zijian Wu; Xiang Nie; Lunfei Du
Journal:  Eur J Med Res       Date:  2022-02-22       Impact factor: 2.175

8.  The comparison of epidemiological characteristics between confirmed and clinically diagnosed cases with COVID-19 during the early epidemic in Wuhan, China.

Authors:  Fang Shi; Haoyu Wen; Rui Liu; Jianjun Bai; Fang Wang; Sumaira Mubarik; Xiaoxue Liu; Yong Yu; Qiumian Hong; Jinhong Cao; Chuanhua Yu
Journal:  Glob Health Res Policy       Date:  2021-05-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.